(51) International Patent Classification [6] :		(11) International Publication Number:	**WO 98/06415**
A61K 38/00	**A2**	(43) International Publication Date:	19 February 1998 (19.02.98)

(21) International Application Number: PCT/US97/13810

(22) International Filing Date: 7 August 1997 (07.08.97)

(30) Priority Data:
08/694,843   9 August 1996 (09.08.96)   US

(71) Applicant: XOMA CORPORATION [US/US]; 2910 Seventh Street, Berkeley, CA 94710-2737 (US).

(72) Inventor: LAMBERT, Lewis, H., Jr.; 45928 Omega Drive, Fremont, CA 94539 (US).

(74) Agent: BORUN, Michael, F.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 S. Wacker Drive, Chicago, IL 60606-6402 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: ANTI-CHLAMYDIAL METHODS AND MATERIALS

(57) Abstract

The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product.

- 1 -

ANTI-CHLAMYDIAL METHODS AND MATERIALS

BACKGROUND OF THE INVENTION

The present invention relates generally to methods of treating
chlamydial infections by administration of bactericidal/permeability-
5   increasing (BPI) protein products.

BPI is a protein isolated from the granules of mammalian
polymorphonuclear leukocytes (PMNs or neutrophils), which are blood
cells essential in the defense against invading microorganisms. Human BPI
protein has been isolated from PMNs by acid extraction combined with
10   either ion exchange chromatography [Elsbach, *J. Biol. Chem.*, *254*:11000
(1979)] or *E. coli* affinity chromatography [Weiss, et al., *Blood*, *69*:652
(1987)]. BPI obtained in such a manner is referred to herein as natural BPI
and has been shown to have potent bactericidal activity against a broad
spectrum of gram-negative bacteria. The molecular weight of human BPI
15   is approximately 55,000 daltons (55 kD). The amino acid sequence of the
entire human BPI protein and the nucleic acid sequence of DNA encoding
the protein have been reported in Figure 1 of Gray et al., *J. Biol. Chem.*,
264:9505 (1989), incorporated herein by reference. The Gray et al. amino
acid sequence is set out in SEQ ID NO: 1 hereto.

20   BPI is a strongly cationic protein. The N-terminal half of
BPI accounts for the high net positive charge; the C-terminal half of the
molecule has a net charge of -3. [Elsbach and Weiss (1981), *supra*.] A
proteolytic N-terminal fragment of BPI having a molecular weight of about
25 kD has an amphipathic character, containing alternating hydrophobic
25   and hydrophilic regions. This N-terminal fragment of human BPI
possesses the anti-bacterial efficacy of the naturally-derived 55 kD human
BPI holoprotein. [Ooi et al., *J. Bio. Chem.*, *262*: 14891-14894 (1987)].
In contrast to the N-terminal portion, the C-terminal region of the isolated
human BPI protein displays only slightly detectable anti-bacterial activity
30   against gram-negative organisms. [Ooi et al., *J. Exp. Med.*, *174*:649

- 2 -

(1991).] An N-terminal BPI fragment of approximately 23 kD, referred to as "rBPI$_{23}$," has been produced by recombinant means and also retains antibacterial activity against gram-negative organisms. Gazzano-Santoro et al., *Infect. Immun.* 60:4754-4761 (1992).

5   The bactericidal effect of BPI has been reported to be highly specific to gram-negative species, e.g., in Elsbach and Weiss, *Inflammation: Basic Principles and Clinical Correlates*, eds. Gallin et al., Chapter 30, Raven Press, Ltd. (1992). This reported target cell specificity was believed to be the result of the strong attraction of BPI for

10   lipopolysaccharide (LPS), which is unique to the outer membrane (or envelope) of gram-negative organisms. Although BPI was commonly thought to be non-toxic for other microorganisms, including yeast, and for higher eukaryotic cells, it has recently been discovered that BPI protein products, as defined *infra*, exhibit activity against gram-positive bacteria,

15   mycoplasma, mycobacteria, fungi, and protozoa. [See allowed, co-owned, co-pending U.S. Patent Application Serial No. 08/372,783 filed January 13, 1995, the disclosures of which are incorporated herein by reference; co-owned, co-pending U.S. Patent Application Serial No. 08/626,646, the disclosures of which are incorporated herein by reference; co-owned, co-

20   pending U.S. Patent Application Serial No. 08/372,105, the disclosures of which are incorporated herein by reference; and co-owned, co-pending U.S. Patent Application Serial No. 08/273,470, the disclosures of which are incorporated herein by reference.] It has also been discovered that BPI protein products have the ability to enhance the activity of antibiotics

25   against bacteria. [See U.S. Patent No. 5,523,288, the disclosures of which are incorporated herein by reference, and allowed, co-owned, co-pending U.S. Patent Application Serial No. 08/372,783.]

           The precise mechanism by which BPI kills gram-negative bacteria is not yet completely elucidated, but it is believed that BPI must

30   first bind to the surface of the bacteria through electrostatic and

- 3 -

hydrophobic interactions between the cationic BPI protein and negatively

charged sites on LPS. LPS has been referred to as "endotoxin" because of

the potent inflammatory response that it stimulates, i.e., the release of

mediators by host inflammatory cells which may ultimately result in

5   irreversible endotoxic shock. BPI binds to lipid A, reported to be the most

toxic and most biologically active component of LPS.

In susceptible gram-negative bacteria, BPI binding is thought

to disrupt LPS structure, leading to activation of bacterial enzymes that

degrade phospholipids and peptidoglycans, altering the permeability of the

10   cell's outer membrane, and initiating events that ultimately lead to cell

death. [Elsbach and Weiss (1992), supra]. BPI is thought to act in two

stages. The first is a sublethal stage that is characterized by immediate

growth arrest, permeabilization of the outer membrane and selective

activation of bacterial enzymes that hydrolyze phospholipids and

15   peptidoglycans. Bacteria at this stage can be rescued by growth in serum

albumin supplemented media [Mannion et al., J. Clin. Invest., 85:853-860

(1990)]. The second stage, defined by growth inhibition that cannot be

reversed by serum albumin, occurs after prolonged exposure of the bacteria

to BPI and is characterized by extensive physiologic and structural changes,

20   including apparent damage to the inner cytoplasmic membrane.

Initial binding of BPI to LPS leads to organizational changes

that probably result from binding to the anionic groups of LPS, which

normally stabilize the outer membrane through binding of Mg^{++} and Ca^{++}.

Attachment of BPI to the outer membrane of gram-negative bacteria

25   produces rapid permeabilization of the outer membrane to hydrophobic

agents such as actinomycin D. Binding of BPI and subsequent gram-

negative bacterial killing depends, at least in part, upon the LPS

polysaccharide chain length, with long O-chain bearing, "smooth"

organisms being more resistant to BPI bactericidal effects than short O-

30   chain bearing, "rough" organisms [Weiss et al., J. Clin. Invest. 65: 619-

- 4 -

628 (1980)]. This first stage of BPI action, permeabilization of the gram-
negative outer envelope, is reversible upon dissociation of the BPI, a
process requiring high concentrations of divalent cations and synthesis of
new LPS [Weiss et al., *J. Immunol. 132*: 3109-3115 (1984)]. Loss of

5   gram-negative bacterial viability, however, is not reversed by processes
which restore the envelope integrity, suggesting that the bactericidal action
is mediated by additional lesions induced in the target organism and which
may be situated at the cytoplasmic membrane (Mannion et al., *J. Clin.
Invest. 86*: 631-641 (1990)). Specific investigation of this possibility has

10   shown that on a molar basis BPI is at least as inhibitory of cytoplasmic
membrane vesicle function as polymyxin B (In't Veld et al., *Infection and
Immunity 56*: 1203-1208 (1988)) but the exact mechanism as well as the
relevance of such vesicles to studies of intact organisms has not yet been
elucidated.

15   Chlamydia are nonmotile, gram-negative, obligate
intracellular bacteria that have unusual biological properties which
phylogenetically distinguish them from other families of bacteria.
Chlamydiae are presently placed in their own order, the *Chlamydiales*,
family *Chlamydiaceae*, with one genus, *Chlamydia*. [Schachter and

20   Stamm, *Chlamydia*, in *Manual of Clinical Microbiology*, pages 669-677,
American Society for Microbiology, Washington, DC (1995).] There are
four species, *Chlamydia trachomatis, C. pneumoniae, C. psittaci and C.
pecorum*, which cause a wide spectrum of human diseases. In developing
countries, *C. trachomatis* causes trachoma, the world's leading cause of

25   preventable blindness. Over 150 million children have active trachoma,
and over 6 million people are currently blind from this disease. In
industrialized countries, *C. trachomatis* is the most prevalent sexually
transmitted disease, causing urethritis, cervicitis, epididymitis, ectopic
pregnancy and pelvic inflammatory disease. Last year alone, an estimated

30   300 million people contracted sexually transmitted chlamydial infections.

- 5 -

Among the 250,000 cases of pelvic inflammatory disease per year in the
United States, approximately 25,000 women are rendered infertile each
year. Neonatal *C. trachomatis* infections, contracted at birth from infected
mothers, cause hundreds of thousands of conjunctivitis cases per year, of
5   which about half of these infected infants develop pneumonia. Recently,
C. pneumoniae has been implicated as a common cause of epidemic human
pneumonitis. Members of the genus are not only important human
pathogens, but also cause significant morbidity in other mammals and
birds. Thus, chlamydia are one of the most ubiquitous pathogens in the
10   animal kingdom. [Zhang et al., *Cell, 69*:861-869 (1992).]

     Their unique developmental cycle differentiates them from
all other microorganisms. They are obligate intracellular parasites that are
unable to synthesize ATP, and thus depend on the host cells' energy to
survive. Unlike viruses, they always contain both DNA and RNA, divide
15   by binary fission, contain ribosomes, and can synthesize proteins.
Chlamydia have cell walls similar in structure to those of gram-negative
bacteria, and all members of the genus carry a unique LPS-like antigen,
termed complement fixation (CF) antigen, that may be analogous to the
LPS of certain gram-negative bacteria. [Schachter and Stamm, *supra.*]
20   Chlamydia also carry a major outer membrane protein (MOMP) that
contains both species and subspecies-specific antigens.

     The infectious form of chlamydia is the elementary body
(EB), which infects mammalian cells by attaching to the host cell and
entering in a host-derived phagocytic vesicle (endosome), within which the
25   entire growth cycle is completed. The target host cell *in vivo* is typically
the columnar epithelial cell, and the primary mode of entry is believed to
be receptor-mediated endocytosis. Once the EB has entered the cell, it
reorganizes into a reticulate body (RB) that is larger than the EB and
metabolically active, synthesizing DNA, RNA and proteins. The EBs are
30   specifically adapted for extracellular survival, while the metabolically

- 6 -

active RBs do not survive well outside the host cell and seems adapted for an intracellular milieu. After approximately 8 hours, the RBs begin dividing by binary fission. As they replicate within the endosomes of host cells, they form characteristic intracellular inclusions that can be seen by

5   light microscopy. After a period of growth and division, the RBs reorganize and condense to form infectious EBs. The developmental cycle is complete when host cell lysis or exocytosis of chlamydia occurs, releasing the EBs to initiate another cycle of infection. The length of the complete developmental cycle, as studied in cell culture models, is 48 to 72

10 hours and varies as a function of the infecting strain, host cell and environmental conditions. [Beatty et al., *Microbiol. Rev.*, *58(4)*:686-699 (1994).]

It has been demonstrated, at least for *C. trachomatis*, that attachment of the chlamydia organism to host cells is mediated by a

15 heparan sulfate-like glycosaminoglycan (GAG) present on the surface of the chlamydia. Treatment of chlamydia with either purified heparin, heparin sulfate, or heparin receptor analogs (such as platelet factor 4 and fibronectin, both of which are known to bind heparin sulfate), inhibited the attachment and infectivity of chlamydia to host cells. Inhibition was not

20 seen with non-heparin GAGs, such as hyaluronate, chondroitin sulfate, or keratin sulfate. Treatment of *C. trachomatis* with heparitinase reduced attachment and infectivity by greater than 90%; subsequent treatment with exogenous heparan sulfate was able to restore the ability of treated organisms to attach to host cells in a dose-dependent manner. Other GAGs

25 such as hyaluronate, chondroitin sulfate, or keratin sulfate did not restore attachment ability. These data suggest that a heparin sulfate-like GAG mediates attachment of chlamydia to host cells by bridging mutual GAG receptors on the host cell surface and on the chlamydial outer membrane surface. [Zhang et al., *Cell*, *69*:861-869 (1992).]

- 7 -

C. trachomatis is almost exclusively a human pathogen, and
is responsible for trachoma, inclusion conjunctivitis, lymphogranuloma
venereum (LGV), and genital tract diseases. [Schachter and Stamm,
supra.] Within this species, serotypes A, B, Ba, and C have been

5   associated with endemic trachoma, the most common preventable form of
blindness in the world. Trachoma is a chronic inflammation of the
conjunctiva and the cornea, which is not sexually transmitted. The
potentially blinding sequelae of trachoma include lid distortion, trichiasis
(misdirection of lashes), and entropion (inward deformation of the lid

10 margin). These can cause corneal ulceration followed by loss of vision.
Serotypes L1, L2, and L3 of *C. trachomatis* are associated with LGV.
Untreated, lymphogranuloma venereum progresses through three stages,
each more severe than the preceding one. The primary lesion, if present,
appears on the genitals. The second stage is a bubonic state marked by

15 regional lymphadenopathy, during which the buboes may suppurate and
develop draining fistulas. Rectal strictures and lymphatic obstruction can
appear in the tertiary stage. Lymphogranuloma venereum is a common
problem in developing countries with tropical or subtropical climates,
especially among the lower socioeconomic groups.

20   *C. trachomatis* is also the most common agent of sexually
transmitted disease. In men, serotypes D through K are the major
identifiable causes of nongonococcal urethritis, and also cause epididymitis,
Reiter's syndrome, and proctitis. Chlamydial infections are not easily
identified in men by clinical symptoms alone, because the infection may be

25 asymptomatic and because other pathogens cause similar symptoms.
Chlamydial urethritis occurs twice as frequently as gonococcal urethritis
(gonorrhea) in some populations, and its incidence is on the increase. Even
when *N. gonorrhea* is shown to be present, the urethritis may be due to a
dual or multiple infection involving a second organism. Concurrent *C.*

30 *trachomatis* and *N. gonorrhoea* infections have been reported in about 25

- 8 -

percent of men with gonorrhea. Epididymitis is the most important

complication of chlamydial urethritis in men. *C. trachomatis* causes one of

every two cases of epididymitis in younger men in the United States, with

sterility a possible result. Reiter's syndrome is another manifestation of

5   chlamydial infection in men. It is a painful systemic illness that classically

includes symptoms of urethritis, conjunctivitis and arthritis. Urethritis and

arthritis are by far the most frequent combination; it appears that the

chlamydial urethral infection may trigger the arthritis. *C. trachomatis* can

also cause proctitis (anal inflammation), particularly in homosexual men.

10   In women, chlamydial infection with the sexually transmitted

serotypes results in cervicitis, urethritis, endometritis, salpingitis, and

proctitis; serious sequelae of salpingitis include tubal scarring, infertility,

and ectopic pregnancy. Unrecognized chlamydial infections in women are

common. Approximately 50 percent of women infected with chlamydia are

15   asymptomatic. *C. trachomatis* causes mucopurulent cervicitis and the

urethral syndrome, as well as endometritis and salpingitis. These upper

genital tract chlamydial infections may cause sterility or predispose to

ectopic pregnancies and are the gravest complications of chlamydial

infections in women. Ten percent of all maternal deaths are due to ectopic

20   pregnancies. *C. trachomatis* causes over 30 percent of the cases of

mucopurulent cervicitis. As many as one-half of the women with

gonococcal cervicitis have a concomitant chlamydial infection. If the

gonococcal infection is treated with penicillin, the concomitant chlamydial

cervicitis will continue undetected and untreated, and may progress to

25   pelvic inflammatory disease (salpingitis), which can lead to sterility and

ectopic pregnancies. *C. trachomatis* is a cause of the urethral syndrome in

women. Chlamydial infections may ascend from the cervix to the

endometrium, where *C. trachomatis* has been found in the epithelial lining

of the uterine cavity. It is estimated that about one-half of all women will

30   cervicitis have endometritis. Salpingitis, a major cause of ectopic

- 9 -

pregnancies and infertility, is the most serious complication of female

genital infections. Upper abdominal pain is the predominant symptom of

perihepatitis. Both *C. trachomatis* and *N. gonorrhoea* can cause

perihepatitis. This condition occurs almost exclusively in women in whom

5   the infecting organisms spread to the surface of the liver from inflamed

fallopian tubes.

Women infected with *C. trachomatis* may also pass the

disease to their newborn as it passes through the infected birth canal.

These newborns most often develop inclusion conjunctivitis or chlamydial

10   pneumonia, but may also develop vaginal, pharyngeal, or enteric

infections. Though not blinding, inclusion conjunctivitis can become

chronic, causing mild scarring and pannus formulation if left untreated.

During passage through the birth canal, up to two-thirds of babies born to

mothers with chlamydial genital infections will also become infected. With

15   as many as one in ten pregnant women having chlamydial cervicitis in

some parts of the world, the risk to newborns is considerable. Chlamydial

pneumonia occurs in 10 percent to 20 percent of infants born to infected

mothers. *C. trachomatis* is responsible for 20 percent to 60 percent of all

pneumonias during the first 6 months of life.

20   *C. trachomatis* strains are sensitive to the action of

tetracyclines, macrolides and sulfonamides and produce a glycogen-like

material within the inclusion vacuole that stains with iodine.

C. psittaci strains infect many avian species and mammals,

producing such diseases as psittacosis, ornithosis, feline pneumonitis, and

25   bovine abortion. [Schachter and Stamm, *supra.*] *C. psittaci* is ubiquitous

among avian species, and infection in birds usually involves the intestinal

tract. The organism is shed in the feces, contaminates the environment,

and is spread by aerosol. *C. psittaci* is also common in domestic

mammals. In some parts of the world, these infections have important

30   economic consequences, as *C. psittaci* is a cause of a number of systemic

- 10 -

and debilitating diseases in domestic mammals and, most important, can
cause abortions. Human chlamydial infections from this agent usually
result from exposure to an infected avian species, but may also occur after
exposure to infected domestic mammals. This species is resistant to the
5   action of sulfonamides and produces inclusions that do not stain with
iodine.

C. *pneumoniae* has less than 10% DNA relatedness to the
other species and has pear-shaped rather than round elementary bodies
(EBs). Like *C. trachomatis*, it appears to be exclusively a human pathogen
10   without an animal reservoir. *C. pneumoniae* has been identified as the
cause of a variety of respiratory tract diseases and is distributed worldwide.
[Schachter and Stamm, *supra.*] Infections appear to be commonly acquired
in later childhood, adolescence, and early adulthood, resulting in
seroprevalences of 40 to 50% in 30 to 40-year-old people. Manifestations
15   of infection include pharyngitis, bronchitis, and mild pneumonia, and
transmission is primarily via respiratory secretions. In seroepidemiological
studies, these infections have been linked with coronary artery disease, and
their role in atherosclerosis is currently under intense scrutiny.

The role of C. *pecorum* as a pathogen is not clear, and
20   specialized reagents are required for its identification.

The recommended procedure for primary isolation of
chlamydia is cell culture. Chlamydia will grow in the yolk sac of the
embryonated hen egg, as well as in cell culture (with some variability). *C.
trachomatis* can infect several cell lines, such as McCoy's heteroploid
25   murine cells, HeLa 229 cells, BHK-21 cells, or L-929 cells. HL cells and
Hep-2 cells may be more sensitive for the recovery of C. *pneumoniae.*
The most common technique involves inoculation of clinical specimens into
cycloheximide-treated McCoy cells. The basic principle involves
centrifugation of the inoculum onto the cell monolayer, incubation of the
30   monolayers for 48 to 72 hours, and demonstration of typical

- 11 -

intracytoplasmic inclusions by appropriate immunofluorescence, iodine or Giemsa staining procedures. Cell culture generally requires two to six days to complete because of the incubation time required.

5   Chlamydia may also be detected in samples by the direct fluorescent antibody (DFA) test, in which slides are incubated with fluorescein-conjugated monoclonal antibodies, and fluorescing elementary bodies are detected using a fluorescent microscope. This test has approximately 80% to 90% sensitivity and 98% to 99% specificity compared with cell cultures when both tests are performed under ideal

10   circumstances. [Schachter and Stamm, *supra.*]

A number of commercially available products can detect chlamydial antigens in clinical specimens by using enzyme immunoassay (EIA) procedures. Most of these products detect chlamydial LPS, which is more soluble than MOMP. Without confirmation, the tests have a

15   specificity on the order of 97%. [Schachter and Stamm, *supra.*] Several nucleic acid probes are also commercially available. One commercially available probe test (GenProbe) utilizes DNA-RNA hybridization in an effort to increase sensitivity by detecting chlamydial RNA.

The complement fixation (CF) test is the most frequently

20   performed serological test, and measures serum level of complement-fixing antibody (antibody to the group CF antigen). It is useful for diagnosing psittacosis, in which paired acute- and convalescent-phase sera often show four-fold or greater increases in titer. The same seems to be true for many C. *pneumoniae* infections. Approximately 50% of these infections are CF-

25   positive, although it may take 24 weeks to detect seroconversion. CF testing may also be useful in diagnosing LGV, in which single-point titers greater than 1:64 are highly supportive of this clinical diagnosis. [Schachter and Stamm, *supra.*] High titers of complement-fixing antibodies are not found in chlamydial conjunctivitis or genital tract infections, and

30   therefore are not sensitive for these infections.

- 12 -

The microimmunofluorescence (micro-IF) method is a much more sensitive procedure for measuring anti-chlamydial antibodies. This indirect fluorescent antibody technique uses antigens prepared by infecting the yolk sacs of fertile chick embryos with each chlamydial serotype.

5   Serial dilutions of patient serum are added to the prepared antigens, and the level of antibody in the blood sample is determined with the use of immunofluorescence. Trachoma, inclusion conjunctivitis, and genital tract infections may be diagnosed by the micro-IF technique if appropriately timed paired sera can be obtained, but the procedure is of limited clinical

10   utility because diagnosis requires demonstration of a four-fold or greater change in antibody titer in paired specimens, and because patients with superficial genital infections such as urethritis may not have a change in titer. However, a high antibody titer in a single serum specimen from a patient with Reiter's syndrome and a high IgM titer in the serum of an

15   infant with pneumonia are helpful in establishing a diagnosis.

Strain-to-strain variation in antimicrobial susceptibility profiles and newly acquired drug resistance are both very infrequent among chlamydia. Among the drugs most active in vitro against *C. trachomatis*, *C. pneumoniae*, and *C. psittaci* are the tetracyclines, such as tetracycline

20   and doxycycline, the macrolides, such as erythromycin and azithromycin, the quinolones, such as ciprofloxacin and ofloxacin, chloramphenicol, rifampin, clindamycin and the sulfonamides. The tetracyclines and macrolides have generally been the mainstays of therapy for infections due to chlamydia. [Schachter and Stamm, *supra*; Goodman and Gilman, *The*

25   *Pharmacological Basis of Therapeutics*, 9th ed., McGraw-Hill, New York, NY (1996).]

Antimicrobial susceptibility testing is infrequently performed for chlamydial infections, but may be conducted as follows. The organisms for testing are grown for at least two passages in cells cultured in

30   antibiotic-free media before being harvested. An adjusted inoculum of

- 13 -

~ 100 inclusion-forming units per microtiter well is then used to infect antibiotic-free cell monolayers. After centrifugation of the inoculum onto the monolayer, serial dilutions of the test antibiotic can be added either immediately or at various time intervals over the next 24 hours. After 48

5   hours, fluorescein-conjugated monoclonal antibodies are use to identify minimum inhibitory concentration (MIC), *i.e.*, the highest antibiotic dilution that inhibits intracellular inclusion formation. Generally, monolayers are also disrupted and further passaged to define the minimum bactericidal concentration (MBC), *i.e.*, the highest antibiotic dilution that

10 prevents viable chlamydia from being detected in passage (MBC).

SUMMARY OF THE INVENTION

The present invention provides methods of treating a subject suffering from a chlamydial infection by administering a therapeutically effective amount of a BPI protein product. This is based on the surprising

15 discoveries that BPI protein products inhibit the infectivity of chlamydia and inhibit the proliferation of chlamydia in an established intracellular infection. The BPI protein products may be administered alone or in conjunction with other known anti-chlamydial agents. When made the subject of adjunctive therapy, the administration of BPI protein products

20 may reduce the amount of non-BPI anti-chlamydial agent needed for effective therapy, thus limiting potential toxic response and/or high cost of treatment. Administration of BPI protein products may also enhance the effect of such agents, accelerate the effect of such agents, or reverse resistance of chlamydia to such agents.

25 In addition, the invention provides a method of killing or inhibiting growth of chlamydia comprising contacting the chlamydia with a BPI protein product. This method can be practiced *in vivo* or in a variety of *in vitro* uses such as use to decontaminate fluids and surfaces and to

- 14 -

sterilize surgical and other medical equipment and implantable devices, including prosthetic joints and indwelling invasive devices.

A further aspect of the invention involves use of a BPI protein product for the manufacture of a medicament for treatment of

5   chlamydial infection. The medicament may include, in addition to a BPI protein product, other chemotherapeutic agents such as non-BPI anti-chlamydial agents.

Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon considering the

10   following detailed description of the invention, which describes the presently preferred embodiments thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the surprising discovery that a BPI protein product can be administered to treat subjects suffering from

15   chlamydial infection, and provides methods of prophylactically or therapeutically treating such infections. Unexpectedly, BPI protein products were demonstrated to have anti-chlamydial activities, as measured, for example, by a reduction in the number of reproductive bodies seen in the host cells. A variety of chlamydial infections, including infections

20   caused by C. trachomatis, C. pneumoniae, C. psittaci and C. pecorum, may be treated according to the invention.

The term "treating" or "treatment" as used herein encompasses both prophylactic and therapeutic treatment.

The BPI protein product may be administered systemically or

25   topically. Systemic routes of administration include oral, intravenous, intramuscular or subcutaneous injection (including into depots for long-term release), intraocular or retrobulbar, intrathecal, intraperitoneal (e.g. by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug, or transdermal. Topical routes include administration in the form of

- 15 -

salves, creams, jellies, ophthalmic drops or opthalmic ointments, ear drops, suppositories, such as vaginal suppositories, or irrigation fluids (for, e.g., irrigation of wounds).

When given parenterally, BPI protein product compositions are generally injected in doses ranging from 1 µg/kg to 100 mg/kg per day, preferably at doses ranging from 0.1 mg/kg to 20 mg/kg per day, and more preferably at doses ranging from 1 to 20 mg/kg/day. The treatment may continue by continuous infusion or intermittent injection or infusion, or a combination thereof, at the same, reduced or increased dose per day for as long as determined by the treating physician. When given topically, BPI protein product compositions are generally applied in unit doses ranging from 1 µg/mL to 1 gm/mL, and preferably in doses ranging from 1 µg/mL to 100 mg/mL. Those skilled in the art can readily optimize effective dosages and monotherapeutic or concurrent administration regimens for BPI protein product and/or other anti-chlamydial agents, as determined by good medical practice and the clinical condition of the individual patient.

The BPI protein product may be administered in conjunction with other anti-chlamydial agents presently known to be effective. Preferred anti-chlamydial agents for this purpose include the tetracyclines, such as tetracycline and doxycycline, the macrolides, such as erythromycin and azithromycin, the quinolones, such as ciprofloxacin and ofloxacin, chloramphenicol, rifampin, clindamycin and the sulfonamides. Concurrent administration of BPI protein product with anti-chlamydial agents is expected to improve the therapeutic effectiveness of the anti-chlamydial agents. This may occur through reducing the concentration of anti-chlamydial agent required to eradicate or inhibit chlamydial growth, e.g., replication. Because the use of some agents is limited by their systemic toxicity or prohibitive cost, lowering the concentration of anti-chlamydial agent required for therapeutic effectiveness reduces toxicity and/or cost of treatment, and thus allows wider use of the agent. Concurrent

- 16 -

administration of BPI protein product and another anti-chlamydial agent

may produce a more rapid or complete bactericidal or bacteriostatic effect

than could be achieved with either agent alone. BPI protein product

administration may reverse the resistance of chlamydia to anti-chlamydial

5   agents. BPI protein product administration may also convert a

bacteriostatic agent into a bactericidal agent.

An advantage of the present invention is that the wide

spectrum of activity of BPI protein products against a variety of organisms,

and the use of BPI protein products as adjunctive therapy to enhance the

10   activity of antibiotics makes BPI protein products an excellent choice for

treating dual or multiple infections with chlamydia and another organism,

such as the gram-negative bacteria *N. gonorrhea*. Thus, BPI protein

products may be especially useful in inhibiting transmission of sexually

transmitted diseases, which often involve dual gonococcal/chlamydial

15   infection. It is therefore contemplated that BPI protein products will be

incorporated into contraceptive compositions and devices, *e.g.*, included in

spermicidal creams or jellies, or coated on the surface of condoms.

Another advantage is the ability to treat chlamydia that have

acquired resistance to known anti-chlamydial agents. A further advantage

20   of concurrent administration of BPI with an anti-chlamydial agent having

undesirable side effects is the ability to reduce the amount of anti-

chlamydial agent needed for effective therapy. The present invention may

also provide quality of life benefits due to, e.g., decreased duration of

therapy, reduced stay in intensive care units or reduced stay overall in the

25   hospital, with the concomitant reduced risk of serious nosocomial (hospital-

acquired) infections.

"Concurrent administration" as used herein includes

administration of the agents together, or before or after each other. The

BPI protein products and anti-chlamydial agents may be administered by

30   different routes. For example, the BPI protein product may be

- 17 -

administered intravenously while the anti-chlamydial agents are
administered intramuscularly, intravenously, subcutaneously, orally or
intraperitoneally. Alternatively, the BPI protein product may be
administered intraperitoneally while the anti-chlamydial agents are

5   administered intraperitoneally or intravenously, or the BPI protein product
may be administered in an aerosolized or nebulized form while the anti-
chlamydial agents are administered, e.g., intravenously. The BPI protein
product and anti-chlamydial agents may be both administered intravenously.
The BPI protein product and anti-chlamydial agents may be given

10   sequentially in the same intravenous line, after an intermediate flush, or
may be given in different intravenous lines. The BPI protein product and
anti-chlamydial agents may be administered simultaneously or sequentially,
as long as they are given in a manner sufficient to allow both agents to
achieve effective concentrations at the site of infection.

15   Concurrent administration of BPI protein product and
antibiotic is expected to provide more effective treatment of chlamydial
infections. Concurrent administration of the two agents may provide
greater therapeutic effects *in vivo* than either agent provides when
administered singly. For example, concurrent administration may permit a

20   reduction in the dosage of one or both agents with achievement of a similar
therapeutic effect. Alternatively, the concurrent administration may
produce a more rapid or complete bactericidal/bacteriostatic effect than
could be achieved with either agent alone.

                Therapeutic effectiveness is based on a successful clinical

25   outcome, and does not require that the anti-chlamydial agent or agents kill
100% of the organisms involved in the infection. Success depends on
achieving a level of anti-chlamydial activity at the site of infection that is
sufficient to inhibit the chlamydia in a manner that tips the balance in favor
of the host. When host defenses are maximally effective, the anti-

30   chlamydial effect required may be minimal. Reducing organism load by

- 18 -

even one log (a factor of 10) may permit the host's own defenses to control the infection. In addition, augmenting an early bactericidal/bacteriostatic effect can be more important than long-term bactericidal/bacteriostatic effect. These early events are a significant and critical part of therapeutic

5   success, because they allow time for host defense mechanisms to activate.

BPI protein product is thought to interact with a variety of host defense elements present in whole blood or serum, including complement, p15 and LBP, and other cells and components of the immune system. Such interactions may result in potentiation of the activities of BPI

10   protein product. Because of these interactions, BPI protein products can be expected to exert even greater activity *in vivo* than *in vitro*. Thus, while *in vitro* tests are predictive of *in vivo* utility, absence of activity *in vitro* does not necessarily indicate absence of activity *in vivo*. For example, BPI has been observed to display a greater bactericidal effect on gram-negative

15   bacteria in whole blood or plasma assays than in assays using conventional media. [Weiss et al., *J. Clin. Invest.* 90:1122-1130 (1992)]. This may be because conventional *in vitro* systems lack the blood elements that facilitate or potentiate BPI's function *in vivo*, or because conventional media contain higher than physiological concentrations of magnesium and calcium, which

20   are typically inhibitors of the activity of BPI protein products. Furthermore, in the host, BPI protein product is available to neutralize translocation of gram-negative bacteria and concomitant release of endotoxin, a further clinical benefit not seen in or predicted by *in vitro* tests.

25   It is also contemplated that the BPI protein product be administered with other products that potentiate the activity of BPI protein products, including the anti-chlamydial activity of BPI protein products. For example, serum complement potentiates the gram-negative bactericidal activity of BPI protein products; the combination of BPI protein product

30   and serum complement provides synergistic bactericidal/growth inhibitory

- 19 -

effects. See, e.g., Ooi *et al. J. Biol. Chem.*, *265*: 15956 (1990) and Levy
et al. J. Biol. Chem., *268*: 6038-6083 (1993) which address naturally-
occurring 15 kD proteins potentiating BPI antibacterial activity. See also
co-owned, co-pending PCT Application No. US94/07834 filed July 13,

5   1994, which corresponds to U.S. Patent Application Serial No. 08/274,303
filed July 11, 1994 as a continuation-in-part of U.S. Patent Application
Serial No. 08/093,201 filed July 14, 1993. These applications, which are
all incorporated herein by reference, describe methods for potentiating
gram-negative bactericidal activity of BPI protein products by administering

10   lipopolysaccharide binding protein (LBP) and LBP protein products. LBP
protein derivatives and derivative hybrids which lack CD-14
immunostimulatory properties are described in PCT Application No.
US94/06931 filed June 17, 1994, which corresponds to co-owned, co-
pending U.S. Patent Application Serial No. 08/261,660, filed June 17,

15   1994 as a continuation-in-part of U.S. Patent Application Serial No.
08/079,510, filed June 17, 1993, the disclosures of all of which are hereby
incorporated by reference. It has also been observed that poloxamer
surfactants enhance the anti-bacterial activity of BPI protein products, as
described in Lambert, U.S. Application Serial No. 08/586,133 filed

20   January 12, 1996, which is a continuation-in-part of U.S. Application
Serial No. 08/530,599 filed September 19, 1995, which is a continuation-
in-part of U.S. Application Serial No. 08/372,104 filed January 13, 1995,
all of which correspond to PCT Application No. PCT/US96/01095;
poloxamer surfactants may also enhance the activity of anti-chlamydial

25   agents.

In addition, the invention provides a method of killing or
inhibiting growth of chlamydia comprising contacting the chlamydia with a
BPI protein product. This method can be practiced *in vivo* or in a variety
of *in vitro* uses such as to decontaminate fluids and surfaces or to sterilize

30   surgical and other medical equipment and implantable devices, including

- 20 -

prostheses and intrauterine devices. These methods can also be used for *in situ* sterilization of indwelling invasive devices such as intravenous lines and catheters, which are often foci of infection.

A further aspect of the invention involves use of a BPI protein product for the manufacture of a medicament for treatment of chlamydial infection. The medicament may include, in addition to a BPI protein product, other chemotherapeutic agents such as anti-chlamydial agents. The medicament can optionally comprise a pharmaceutically acceptable diluent, adjuvant or carrier.

As used herein, "BPI protein product" includes naturally and recombinantly produced BPI protein; natural, synthetic, and recombinant biologically active polypeptide fragments of BPI protein; biologically active polypeptide variants of BPI protein or fragments thereof, including hybrid fusion proteins and dimers; biologically active polypeptide analogs of BPI protein or fragments or variants thereof, including cysteine-substituted analogs; and BPI-derived peptides. The BPI protein products administered according to this invention may be generated and/or isolated by any means known in the art. U.S. Patent No. 5,198,541, the disclosure of which is incorporated herein by reference, discloses recombinant genes encoding, and methods for expression of, BPI proteins including recombinant BPI holoprotein, referred to as rBPI and recombinant fragments of BPI. Co-owned, copending U.S. Patent Application Ser. No. 07/885,501 and a continuation-in-part thereof, U.S. Patent Application Ser. No. 08/072,063 filed May 19, 1993 and corresponding PCT Application No. 93/04752 filed May 19, 1993, which are all incorporated herein by reference, disclose novel methods for the purification of recombinant BPI protein products expressed in and secreted from genetically transformed mammalian host cells in culture and discloses how one may produce large quantities of recombinant BPI products suitable for incorporation into stable, homogeneous pharmaceutical preparations.

- 21 -

Biologically active fragments of BPI (BPI fragments) include biologically active molecules that have the same or similar amino acid sequence as a natural human BPI holoprotein, except that the fragment molecule lacks amino-terminal amino acids, internal amino acids, and/or
5   carboxy-terminal amino acids of the holoprotein. Nonlimiting examples of such fragments include a N-terminal fragment of natural human BPI of approximately 25 kD, described in Ooi et al., *J. Exp. Med.*, *174*:649 (1991), and the recombinant expression product of DNA encoding N-terminal amino acids from 1 to about 193 to 199 of natural human BPI,
10   described in Gazzano-Santoro et al., *Infect. Immun.* *60*:4754-4761 (1992), and referred to as rBPI$_{23}$. In that publication, an expression vector was used as a source of DNA encoding a recombinant expression product (rBPI$_{23}$) having the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in Figure 1 of Gray
15   et al., *supra*, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). Recombinant holoprotein (rBPI) has also been produced having the sequence (SEQ ID NOS: 145 and 146) set out in Figure 1 of Gray et al., *supra*, with the exceptions noted for rBPI$_{23}$ and
20   with the exception that residue 417 is alanine (specified by GCT) rather than valine (specified by GTT). Other examples include dimeric forms of BPI fragments, as described in co-owned and co-pending U.S. Patent Application Serial No. 08/212,132, filed March 11, 1994, and corresponding PCT Application No. PCT/US95/03125, the disclosures of
25   which are incorporated herein by reference. Preferred dimeric products include dimeric BPI protein products wherein the monomers are amino-terminal BPI fragments having the N-terminal residues from about 1 to 175 to about 1 to 199 of BPI holoprotein. A particularly preferred dimeric product is the dimeric form of the BPI fragment having N-terminal residues
30   1 through 193, designated rBPI$_{42}$ dimer.

- 22 -

Biologically active variants of BPI (BPI variants) include but are not limited to recombinant hybrid fusion proteins, comprising BPI holoprotein or biologically active fragment thereof and at least a portion of at least one other polypeptide, and dimeric forms of BPI variants.

5   Examples of such hybrid fusion proteins and dimeric forms are described by Theofan et al. in co-owned, copending U.S. Patent Application Serial No. 07/885,911, and a continuation-in-part application thereof, U.S. Patent Application Serial No. 08/064,693 filed May 19, 1993 and corresponding PCT Application No. US93/04754 filed May 19, 1993, which are all

10   incorporated herein by reference and include hybrid fusion proteins comprising, at the amino-terminal end, a BPI protein or a biologically active fragment thereof and, at the carboxy-terminal end, at least one constant domain of an immunoglobulin heavy chain or allelic variant thereof.

15   Biologically active analogs of BPI (BPI analogs) include but are not limited to BPI protein products wherein one or more amino acid residues have been replaced by a different amino acid. For example, co-owned, copending U.S. Patent Application Ser. No. 08/013,801 filed February 2, 1993 and corresponding PCT Application No. US94/01235

20   filed February 2, 1994, the disclosures of which are incorporated herein by reference, discloses polypeptide analogs of BPI and BPI fragments wherein a cysteine residue is replaced by a different amino acid. A stable BPI protein product described by this application is the expression product of DNA encoding from amino acid 1 to approximately 193 or 199 of the N-

25   terminal amino acids of BPI holoprotein, but wherein the cysteine at residue number 132 is substituted with alanine and is designated $rBPI_{21}\Delta cys$ or $rBPI_{21}$. Other examples include dimeric forms of BPI analogs; e.g. co-owned and co-pending U.S. Patent Application Serial No. 08/212,132 filed March 11, 1994, and corresponding PCT Application No.

- 23 -

PCT/US95/03125, the disclosures of which are incorporated herein by
reference.

Other BPI protein products useful according to the methods
of the invention are peptides derived from or based on BPI produced by

5   recombinant or synthetic means (BPI-derived peptides), such as those
described in co-owned and copending PCT Application No. US94/10427
filed September 15, 1994, which corresponds to U.S. Patent Application
Serial No. 08/306,473, filed September 15, 1994, and PCT Application
No. US94/02465 filed March 11, 1994, which corresponds to U.S. Patent

10   Application Serial No. 08/209,762, filed March 11, 1994, which is a
continuation-in-part of U.S. Patent Application Serial No. 08/183,222, filed
January 14, 1994, which is a continuation-in-part of U.S. Patent
Application Ser. No. 08/093,202 filed July 15, 1993 (for which the
corresponding international application is PCT Application No.

15   US94/02401 filed March 11, 1994), which is a continuation-in-part of U.S.
Patent Application Ser. No. 08/030,644 filed March 12, 1993, the
disclosures of all of which are incorporated herein by reference.

Presently preferred BPI protein products include
recombinantly-produced N-terminal fragments of BPI, especially those

20   having a molecular weight of approximately between 21 to 25 kD such as
$rBPI_{21}$ or $rBPI_{23}$, or dimeric forms of these N-terminal fragments (e.g.,
$rBPI_{42}$ dimer). Additionally, preferred BPI protein products include rBPI
and BPI-derived peptides.

The administration of BPI protein products is preferably

25   accomplished with a pharmaceutical composition comprising a BPI protein
product and a pharmaceutically acceptable diluent, adjuvant, or carrier.
The BPI protein product may be administered without or in conjunction
with known surfactants, other chemotherapeutic agents or additional known
anti-chlamydial agents. A stable pharmaceutical composition containing

30   BPI protein products (e.g., rBPI, $rBPI_{23}$) comprises the BPI protein product

- 24 -

at a concentration of 1 mg/ml in citrate buffered saline (5 or 20 mM

citrate, 150 mM NaCl, pH 5.0) comprising 0.1% by weight of poloxamer

188 (Pluronic F-68, BASF Wyandotte, Parsippany, NJ) and 0.002% by

weight of polysorbate 80 (Tween 80, ICI Americas Inc., Wilmington, DE).

5   Another stable pharmaceutical composition containing BPI protein products

(e.g., rBPI$_{21}$) comprises the BPI protein product at a concentration of 2

mg/ml in 5 mM citrate, 150 mM NaCl, 0.2% poloxamer 188 and 0.002%

polysorbate 80. Such preferred combinations are described in co-owned,

co-pending PCT Application No. US94/01239 filed February 2, 1994,

10   which corresponds to U.S. Patent Application Ser. No. 08/190,869 filed

February 2, 1994 and U.S. Patent Application Ser. No. 08/012,360 filed

February 2, 1993, the disclosures of all of which are incorporated herein

by reference.

          Other aspects and advantages of the present invention will be

15   understood upon consideration of the following illustrative examples.

Example 1 addresses the use of BPI protein product to inhibit infection of

host cells with chlamydia when administered at the same time as

chlamydial challenge. Example 2 addresses the anti-chlamydial activity of

BPI protein product in chlamydia-infected host cells.

20   **Example 1**

                    USE OF BPI PROTEIN PRODUCT TO INHIBIT

                    INFECTION OF HOST CELLS WITH CHLAMYDIA

       A. Preparation of _Chlamydia_ Stock

                    Chlamydia trachomatis (_Ct_) serovar L2 stock was prepared

25   as follows. McCoy cells (ATCC Accession No. CRL 1696) were cultured

overnight in growth medium [Eagles Medium Nutrient Mixture (MEM),

M-3786, Sigma, St. Louis, MO] with 1% sodium pyruvate (S-8636,

Sigma) and 10% fetal bovine serum (FBS, A115-L, Hyclone, Logan, VT).

- 25 -

The media was aspirated and a vial of *Ct* was rapidly thawed and mixed

with 30 mL of Dulbecco's phosphate buffered saline (PBS, Sigma) and 7%

sucrose (DPBS-7). Ten mL of the suspension were added to each of 3

T150 flasks and the flasks were incubated at 37°C while being rocked

5   periodically over the next two hours to distribute the inoculum. The

DPBS-7 was aspirated from the flasks and 50 mL of growth media were

added to each flask. After incubation for three days at 37°C in 5% CO_2,

the *Ct* was harvested as follows. The growth media was aspirated from the

flasks and glass beads were added to the flasks to a depth of ~0.25 inches.

10   Ten mL Eagles MEM (without FBS) was added to each flask and the beads

were rocked over the monolayer until all the cells were dislodged. The

beads and cell debris were collected in 50 mL screw-capped centrifuge

tubes, the flasks were washed twice with PBS, and the washings were

added to the bead suspension. Each tube was placed on ice and sonicated

15   for 60 seconds to disrupt the cells. The disrupted cells/bead suspension

were centrifuged at low speed (~800 rpm). The supernatant was removed

and collected in a 250 mL polycarbonate centrifuge bottle, then centrifuged

for one hour at high speed (~25,000 x g). The pellet was resuspended in

FBS (40 mL) by repeated passage through a #16 gauge needle and syringe.

20   One mL aliquots were distributed into NUNC® (Naperville, IL) cryovials

and frozen at -70°C.

B.   Titration of *Chlamydia* Stock

Three vials of *Ct* stock prepared as described above in

Section A were rapidly thawed at 37°C and serially diluted in 10-fold

25   concentrations in Eagles MEM or DPBS-7 without serum. Twenty-four

well plates with coverslips in each well containing 24-hour McCoy cell

monolayers were prepared. The media was aspirated, the wells were

washed once with PBS, and 1 mL of each *Ct* dilution in either Eagles

MEM or DPBS-7 was added to quadruplicate sets of McCoy cells. The

- 26 -

plates were incubated at 37°C in 5% CO_2 for 2 hours, the media was aspirated, and 2 mL of growth media was added. The plates were then reincubated at 27 °C in 5%CO_2 for 3 days, fixed in methanol, and stained for 30 minutes in a moist chamber with an FITC-labelled mouse

5   monoclonal anti-chlamydia antibody (Syva MicroTrak® Chlamydia trachomatis Culture Confirmation Test). The stained coverslips were washed in water, air dried, inverted into a drop of mounting fluid (50% glycerol; 50% PBS) and viewed using a Leitz fluorescent microscope with a 25X objective (excitation wavelength 480nm, emission wavelength 520

10   nm). The inclusion bodies were counted and comparable results were obtained over the 10^{-2} to 10^{-10} concentration range tested in the Eagles MEM and DPBS-7. The 10^{-5} dilution of the stock preparation gave 100- 300 inclusion body-forming units/mL; this dilution was selected for use in all subsequent studies using this Ct stock. Additional media studies were

15   performed using Basal Medium Eagle (BME, Sigma), Eagles MEM (E- MEM, Sigma), RPMI-1640 with HEPES (Sigma), RPMI-1640 without HEPES (Sigma), F-12 (Gibco) and Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 Ham (DMEM/F-12, Gibco). DMEM/F-12 without FBS was selected for use in subsequent *Chlamydia* infectivity studies.

20   Media without FBS was selected for use because the addition of 10% FBS to the above tested media inhibited infection of McCoy cells by Ct.

C. Infection by *Chlamydia* in the Presence or Absence of BPI Protein Product

The BPI protein product tested was rBPI$_{21}$ [2 mg/mL in

25   5mM sodium citrate, 150 mM sodium chloride, pH 5.0, with 0.2% PLURONIC® P123 (BASF Wyandotte, Parsippany, NJ), 0.002% polysorbate 80 (TWEEN® 80, ICI Americas Inc., Wilmington, DE) and 0.05% EDTA]. Equal volumes of formulation buffer alone [5mM sodium citrate, 150 mM sodium chloride, pH 5.0, with 0.2% PLURONIC® P123,

- 27 -

0.002% polysorbate 80 and 0.05% EDTA] were used as a control. Serial
dilutions of rBPI$_{21}$ or formulation buffer were prepared with DMEM/F-12
(without FBS) so that when the serial dilutions were added at a 9:1 ratio to
1 mL of a 10^{-4} dilution of Ct stock, the final concentration of Ct would be
a 10^{-5} dilution of Ct stock and the final rBPI$_{21}$ concentrations would be 128,
64, 32, 16 and 8 μg/mL. Comparable (by volume) formulation buffer
controls were also prepared. The final suspensions were incubated at 37°C
for 30 minutes in a water bath.

McCoy cells in DMEM/F-12/10%FBS were seeded at 2 x
10^5 cells/well into 24-well tissue culture plates (Corning #25820), incubated
for 24 hours and the media aspirated. Ct, with and without BPI, was
added in 1 mL to duplicate wells at each rBPI$_{21}$ concentration. The plates
were centrifuged at 2500 rpm for 30 minutes, incubated for 2 hours at 37°C
in 5% CO_2, and the wells aspirated. Each well received 2 mL of
DMEM/F-12/10%FBS and 1 μg/mL cycloheximide (Sigma) and the plates
reincubated for 3 days. After removal of the media, the wells were washed
with phosphate buffered saline (PBS), air dried, fixed with methanol and
stained with Gram's iodine. The cells may be alternatively stained with
FITC-labelled anti-chlamydia antibodies as described in section B above.

Using an inverted microscope, 100% of each well was
scanned for the presence of inclusion bodies, which stain brown with
Gram's iodine due to the high concentration of glycogen in vacuoles
produced by the reproductive bodies. Results are shown below in Table 1.

- 28 -

Table 1

Number of Inclusion Bodies per Well

	with rBPI$_{21}$ (mean of 4 wells)	without rBPI$_{21}$ (value for 1 well)
128 μg/mL	0	110
64 μg/mL	0	115
32 μg/mL	0	115
16 μg/mL	1.5	114
8 μg/mL	59	124
Positive Control (Ct only)		151
Negative Control (no Ct)		0

These representative results from one of three studies indicate that rBPI$_{21}$ can inhibit infection of permissive cells.

Example 2
ANTI-CHLAMYDIAL ACTIVITY OF BPI PROTEIN
PRODUCT AGAINST CHLAMYDIA-INFECTED HOST CELLS

Chlamydia trachomatis (*Ct*) serovar L2 stock prepared as described in Example 1 was diluted to 10^{-5} with Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 Ham (DMEM/F-12) with 10% fetal bovine serum (FBS).

McCoy cells in DMEM/F-12/10%FBS were seeded at 1 X 10^5 cells/well into 24-well tissue culture plates (Corning #25820), incubated for 24 hours, and the media aspirated. *Ct* (1 mL of the 10^{-5} stock) was added to each well of four plates except for two negative control wells per

- 29 -

plate. The plates were centrifuged at 2500 rpm for 30 minutes, incubated for 24 hours at 37°C in 5% CO_2, and the wells aspirated.

rBPI$_{21}$ as described in Example 1 was diluted to final concentrations of 128, 64, 32, 16 and 8 μg/mL in DMEM/F-12 and 1.0

5 mL added to the appropriate duplicate wells on each plate. Comparable formulation buffer controls as described in Example 1 were also prepared. The plates were incubated for 2 hours, and 1 mL of DMEM/F-12/20%FBS and 2 μg/mL cycloheximide was added to all wells, causing the rBPI$_{21}$ concentration to decrease by a factor of two. The plates were reincubated

10 for up to 5 days.

At 24, 48, 72 and 120 hours, the media was removed from a single plate, the wells washed with PBS and air dried, fixed with methanol and stained with Gram's iodine. Using an inverted microscope, 100% of each well was scanned for the presence of inclusion bodies. Results are

15 shown in Table 2 below.

Table 2

Initial rBPI$_{21}$ Concentration*	Number of Inclusion Bodies Per Well		
	at 24 hours	at 48 hours	at 72 hours
0	285.5	398	335.75
8	194.5	180	108
16	138	140.5	109.5
32	112.5	95	57.5
64	119.5	81	39
128	113	77.5	5

20

25 *This initial concentration, which was present for the first two hours of incubation, was decreased to half of the initial value for the remainder of the 5-day incubation.

- 30 -

These representative results from one of two studies show that $rBPI_{21}$ at
initial concentrations ranging from 16 $\mu g/mL$ to 128 $\mu g/mL$ was able to
reduce the number of intracellular inclusion bodies in Ct-infected cells
when administered 24 hours after challenge with Ct.

5   Numerous modifications and variations in the practice of the
invention are expected to occur to those skilled in the art upon
consideration of the foregoing description on the presently preferred
embodiments thereof. Consequently the only limitations which should be
placed upon the scope of the present invention are those that appear in the
10   appended claims.

- 31 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

    (i) APPLICANT: XOMA Corporation

    (ii) TITLE OF INVENTION: Anti-Chlamydial Methods and Materials

    (iii) NUMBER OF SEQUENCES: 2

    (iv) CORRESPONDENCE ADDRESS:
        (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
        (B) STREET: 6300 Sears Tower, 233 South Wacker Drive
        (C) CITY: Chicago
        (D) STATE: Illinois
        (E) COUNTRY: United States of America
        (F) ZIP: 60606-6402

    (v) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

    (vi) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER:
        (B) FILING DATE:
        (C) CLASSIFICATION:

    (vii) PRIOR APPLICATION DATA:
        (A) APPLICATION NUMBER:
        (B) FILING DATE:
        (C) CLASSIFICATION:

    (viii) ATTORNEY/AGENT INFORMATION:
        (A) NAME: Borun, Michael F.
        (B) REGISTRATION NUMBER: 25,447
        (C) REFERENCE/DOCKET NUMBER: 27129/33433

    (ix) TELECOMMUNICATION INFORMATION:
        (A) TELEPHONE: 312/474-6300
        (B) TELEFAX: 312/474-0448
        (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

    (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 1813 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: single
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: cDNA

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 31..1491

    (ix) FEATURE:
        (A) NAME/KEY: mat_peptide

- 32 -

(B) LOCATION: 124..1491

(ix) FEATURE:
    (A) NAME/KEY: misc_feature

    (D) OTHER INFORMATION: "rBPI"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
CAGGCCTTGA GGTTTTGGCA GCTCTGGAGG ATG AGA GAG AAC ATG GCC AGG GGC        54
                                   Met Arg Glu Asn Met Ala Arg Gly
                                   -31 -30                   -25

CCT TGC AAC GCG CCG AGA TGG GTG TCC CTG ATG GTG CTC GTC GCC ATA        102
Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile
            -20             -15                   -10

GGC ACC GCC GTG ACA GCG GCC GTC AAC CCT GGC GTC GTG GTC AGG ATC        150
Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile
         -5                   1               5

TCC CAG AAG GGC CTG GAC TAC GCC AGC CAG CAG GGG ACG GCC GCT CTG        198
Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu
 10                  15                  20                  25

CAG AAG GAG CTG AAG AGG ATC AAG ATT CCT GAC TAC TCA GAC AGC TTT        246
Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe
                30                  35                  40

AAG ATC AAG CAT CTT GGG AAG GGG CAT TAT AGC TTC TAC AGC ATG GAC        294
Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe Tyr Ser Met Asp
                45                  50                  55

ATC CGT GAA TTC CAG CTT CCC AGT TCC CAG ATA AGC ATG GTG CCC AAT        342
Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val Pro Asn
            60                  65                  70

GTG GGC CTT AAG TTC TCC ATC AGC AAC GCC AAT ATC AAG ATC AGC GGG        390
Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser Gly
        75                  80                  85

AAA TGG AAG GCA CAA AAG AGA TTC TTA AAA ATG AGC GGC AAT TTT GAC        438
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn Phe Asp
 90                  95                  100                 105

CTG AGC ATA GAA GGC ATG TCC ATT TCG GCT GAT CTG AAG CTG GGC AGT        486
Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu Gly Ser
                110                 115                 120

AAC CCC ACG TCA GGC AAG CCC ACC ATC ACC TGC TCC AGC TGC AGC AGC        534
Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys Ser Ser
                125                 130                 135

CAC ATC AAC AGT GTC CAC GTG CAC ATC TCA AAG AGC AAA GTC GGG TGG        582
His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp
                140                 145                 150

CTG ATC CAA CTC TTC CAC AAA AAA ATT GAG TCT GCG CTT CGA AAC AAG        630
Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys
 155                 160                 165
```

- 33 -

```
ATG AAC AGC CAG GTC TGC GAG AAA GTG ACC AAT TCT GTA TCC TCC AAG    678
Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser Ser Lys
170             175                 180                 185

CTG CAA CCT TAT TTC CAG ACT CTG CCA GTA ATG ACC AAA ATA GAT TCT    726
Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile Asp Ser
                190                 195                 200

GTG GCT GGA ATC AAC TAT GGT CTG GTG GCA CCT CCA GCA ACC ACG GCT    774
Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr Thr Ala
                205                 210                 215

GAG ACC CTG GAT GTA CAG ATG AAG GGG GAG TTT TAC AGT GAG AAC CAC    822
Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu Asn His
            220                 225                 230

CAC AAT CCA CCT CCC TTT GCT CCA CCA GTG ATG GAG TTT CCC GCT GCC    870
His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro Ala Ala
        235                 240                 245

CAT GAC CGC ATG GTA TAC CTG GGC CTC TCA GAC TAC TTC TTC AAC ACA    918
His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe Asn Thr
250             255                 260                 265

GCC GGG CTT GTA TAC CAA GAG GCT GGG GTC TTG AAG ATG ACC CTT AGA    966
Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr Leu Arg
                270                 275                 280

GAT GAC ATG ATT CCA AAG GAG TCC AAA TTT CGA CTG ACA ACC AAG TTC   1014
Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr Lys Phe
                285                 290                 295

TTT GGA ACC TTC CTA CCT GAG GTG GCC AAG AAG TTT CCC AAC ATG AAG   1062
Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe Pro Asn Met Lys
            300                 305                 310

ATA CAG ATC CAT GTC TCA GCC TCC ACC CCG CCA CAC CTG TCT GTG CAG   1110
Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser Val Gln
        315                 320                 325

CCC ACC GGC CTT ACC TTC TAC CCT GCC GTG GAT GTC CAG GCC TTT GCC   1158
Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala Phe Ala
330             335                 340                 345

GTC CTC CCC AAC TCC TCC CTG GCT TCC CTC TTC CTG ATT GGC ATG CAC   1206
Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly Met His
                350                 355                 360

ACA ACT GGT TCC ATG GAG GTC AGC GCC GAG TCC AAC AGG CTT GTT GGA   1254
Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu Val Gly
                365                 370                 375

GAG CTC AAG CTG GAT AGG CTG CTC CTG GAA CTG AAG CAC TCA AAT ATT   1302
Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser Asn Ile
            380                 385                 390

GGC CCC TTC CCG GTT GAA TTG CTG CAG GAT ATC ATG AAC TAC ATT GTA   1350
Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr Ile Val
        395                 400                 405

CCC ATT CTT GTG CTG CCC AGG GTT AAC GAG AAA CTA CAG AAA GGC TTC   1398
Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys Gly Phe
410             415                 420                 425
```

- 34 -

```
CCT CTC CCG ACG CCG GCC AGA GTC CAG CTC TAC AAC GTA GTG CTT CAG        1446
Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln
            430             435             440

CCT CAC CAG AAC TTC CTG CTG TTC GGT GCA GAC GTT GTC TAT AAA            1491
Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr Lys
            445             450             455

TGAAGGCACC AGGGGTGCCG GGGGCTGTCA GCCGCACCTG TTCCTGATGG GCTGTGGGGC      1551

ACCGGCTGCC TTTCCCCAGG GAATCCTCTC CAGATCTTAA CCAAGAGCCC CTTGCAAACT      1611

TCTTCGACTC AGATTCAGAA ATGATCTAAA CACGAGGAAA CATTATTCAT TGGAAAAGTG      1671

CATGGTGTGT ATTTTAGGGA TTATGAGCTT CTTTCAAGGG CTAAGGCTGC AGAGATATTT      1731

CCTCCAGGAA TCGTGTTTCA ATTGTAACCA AGAAATTTCC ATTTGTGCTT CATGAAAAAA      1791

AACTTCTGGT TTTTTTCATG TG                                               1813
```

(2) INFORMATION FOR SEQ ID NO:2:

      (i) SEQUENCE CHARACTERISTICS:
         (A) LENGTH: 487 amino acids
         (B) TYPE: amino acid
         (D) TOPOLOGY: linear

      (ii) MOLECULE TYPE: protein

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val
-31 -30             -25             -20

Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val
-15             -10             -5                1

Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala
            5               10              15

Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys
        20              25              30

Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly
    35              40              45

His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser
50              55              60              65

Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser
            70              75              80

Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe
            85              90              95

Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile
        100             105             110

Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr
    115             120             125
```

- 35 -

```
Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His
130               135               140               145

Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys
              150               155               160

Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys
              165               170               175

Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu
          180               185               190

Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu
      195               200               205

Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys
210               215               220               225

Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro
              230               235               240

Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly
          245               250               255

Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala
      260               265               270

Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser
    275               280               285

Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val
290               295               300               305

Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser
              310               315               320

Thr Pro Pro His Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro
          325               330               335

Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala
      340               345               350

Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser
    355               360               365

Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu
370               375               380               385

Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu
              390               395               400

Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val
          405               410               415

Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val
      420               425               430

Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe
    435               440               445

Gly Ala Asp Val Val Tyr Lys
450               455
```

- 36 -

WHAT IS CLAIMED ARE:

1. A method of treating chlamydial infections comprising administering to a subject suffering from a chlamydial infection a therapeutically effective amount of a bactericidal/permeability-increasing (BPI) protein product.

2. The method of claim 1 wherein the BPI protein product is an N-terminal fragment of BPI or dimeric form thereof.

3. The method of claim 3 wherein the N-terminal fragment has a molecular weight of approximately between 21 kD and 25 kD.

4. The method of claim 1 wherein the BPI protein product is BPI holoprotein, $rBPI_{23}$ or $rBPI_{21}$.

5. The method of claim 1 wherein the BPI protein product is administered orally or parenterally at a dose of between 1 μg/kg to 100 mg/kg per day.

6. The method of claim 1 wherein the BPI protein product is administered topically at a unit dose of between 1 μg/mL to 1 gm/mL.

7. The method of claim 1 wherein the chlamydial infection involves a chlamydial species selected from the group consisting of _C. trachomatis, C. pneumoniae, C. psittaci_ and _C. pecorum_ species.

8. The method of claim 6 wherein the chlamydial species is _C. trachomatis_.

- 37 -

9. The method of claim 1 comprising the additional step of administering a non-BPI anti-chlamydial agent.

10. A method of killing or inhibiting replication of chlamydia comprising contacting the chlamydia with a bactericidal/permeability-increasing (BPI) protein product.

11. The method of claim 10 further comprising contacting the chlamydial species with a non-BPI anti-chlamydial agent.